Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Company News

China approves first biosimilar, Shanghai Henlius’ HLX01

February 25, 2019 11:45 PM UTC

China's National Medical Products Administration (NMPA) approved last Friday the country’s first biosimilar, rituximab biosimilar HLX01 from Shanghai Henlius Biotech Inc. (Shanghai, China).

The chimeric mAb against CD20 was approved in China for the same indications as its reference drug, Rituxan rituximab from Roche (SIX:ROG; OTCQX:RHHBY), including for recurrent or drug-resistant follicular central lymphoma, CD20-positive stage III-IV follicular non-Hodgkin lymphoma (NHL) and CD20-positive diffuse large B cell lymphoma (DLBCL)...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article